Budd-Chiari syndrome secondary prevention: Difference between revisions
Mazia Fatima (talk | contribs) |
No edit summary |
||
(6 intermediate revisions by one other user not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Budd-Chiari syndrome}} | {{Budd-Chiari syndrome}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{Mazia}} | ||
{{ | |||
==Overview== | ==Overview== | ||
[[Secondary prevention]] strategies following Budd-Chiari syndrome include various measures such as, initiation of [[anticoagulation]] immediately in patients to [[Prevention (medical)|prevent]] propagation of the [[clot]], provided there are no [[contraindications]]. Effective management of [[esophageal varices]]. [[Patients]] with Budd-Chiari syndrome treated with balloon [[dilatation]] or [[stents]] require follow-up [[Catheterization|catheterizations]] and repeat dilatations or [[stent]] replacement. All [[patients]] should have routine surveillance for [[Hepatocellular carcinoma|hepatocellular carcinoma (HCC)]]. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
Secondary prevention strategies following Budd-Chiari syndrome include: | [[Secondary prevention]] strategies following Budd-Chiari syndrome include: <ref name="pmid26494427">{{cite journal |vauthors=Goel RM, Johnston EL, Patel KV, Wong T |title=Budd-Chiari syndrome: investigation, treatment and outcomes |journal=Postgrad Med J |volume=91 |issue=1082 |pages=692–7 |year=2015 |pmid=26494427 |doi=10.1136/postgradmedj-2015-133402 |url=}}</ref><ref name="pmid23411869">{{cite journal |vauthors=Ren W, Qi X, Yang Z, Han G, Fan D |title=Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review |journal=Eur J Gastroenterol Hepatol |volume=25 |issue=7 |pages=830–41 |year=2013 |pmid=23411869 |doi=10.1097/MEG.0b013e32835eb8d4 |url=}}</ref> | ||
*[[Anticoagulation]] should be initiated immediately in patients to prevent propagation of the [[clot]], provided there are no [[contraindications]]. | |||
*Effective management of [[esophageal varices]]. | |||
*Patients with Budd-Chiari syndrome treated with balloon dilatation or [[stents]] require follow-up [[Catheterization|catheterizations]] and repeat dilatations or [[Stent|stent replacement]]. | |||
*All patients should have routine surveillance for [[Hepatocellular carcinoma|hepatocellular carcinoma (HCC).]] | |||
==References== | ==References== |
Latest revision as of 21:39, 1 December 2017
Budd-Chiari syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Budd-Chiari syndrome secondary prevention On the Web |
American Roentgen Ray Society Images of Budd-Chiari syndrome secondary prevention |
Risk calculators and risk factors for Budd-Chiari syndrome secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]
Overview
Secondary prevention strategies following Budd-Chiari syndrome include various measures such as, initiation of anticoagulation immediately in patients to prevent propagation of the clot, provided there are no contraindications. Effective management of esophageal varices. Patients with Budd-Chiari syndrome treated with balloon dilatation or stents require follow-up catheterizations and repeat dilatations or stent replacement. All patients should have routine surveillance for hepatocellular carcinoma (HCC).
Secondary Prevention
Secondary prevention strategies following Budd-Chiari syndrome include: [1][2]
- Anticoagulation should be initiated immediately in patients to prevent propagation of the clot, provided there are no contraindications.
- Effective management of esophageal varices.
- Patients with Budd-Chiari syndrome treated with balloon dilatation or stents require follow-up catheterizations and repeat dilatations or stent replacement.
- All patients should have routine surveillance for hepatocellular carcinoma (HCC).
References
- ↑ Goel RM, Johnston EL, Patel KV, Wong T (2015). "Budd-Chiari syndrome: investigation, treatment and outcomes". Postgrad Med J. 91 (1082): 692–7. doi:10.1136/postgradmedj-2015-133402. PMID 26494427.
- ↑ Ren W, Qi X, Yang Z, Han G, Fan D (2013). "Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review". Eur J Gastroenterol Hepatol. 25 (7): 830–41. doi:10.1097/MEG.0b013e32835eb8d4. PMID 23411869.